Toxic shock syndrome is an acute, toxin-mediated, life-threatening illness caused by superantigen-producing strains of Staphylococcus aureus (TSST-1) or Streptococcus pyogenes (Group A Strep), characterized by fulminant onset of fever, diffuse erythroderma, hypotension, and multiorgan failure. [1-2] Incidence is approximately 0.03–0.50 per 100,000; mortality is ~8% for menstrual TSS and 30–80% for streptococcal TSS in adults. [3-4] Multi-organ failure can develop within 8–12 hours of symptom onset. [2]
1. History
- Onset and timing: Abrupt onset of flu-like illness — fever, chills, severe myalgia, malaise. Menstrual TSS: onset during menses in ~95% of cases [2]
- Tampon/device use: Type, absorbency, duration of wear (>8 hours is a risk factor), menstrual cup use [5]
- Surgical/wound history: Post-operative TSS typically occurs within 48 hours of surgery, often without overt wound infection [2]
- GI symptoms: Profuse watery diarrhea and vomiting are early and prominent [1][6]
- Skin changes: Ask about diffuse rash ("sunburn-like"), later peeling of palms/soles
- Neurologic symptoms: Confusion, agitation, lethargy, syncope [2]
- Other sources: Burns, nasal packing, soft tissue injuries, postpartum/postabortion, pharyngitis [1]
- Important negatives: No focal neurologic deficits (distinguishes from meningitis), no vesicular rash (distinguishes from varicella-associated streptococcal TSS)
2. Alarm Features
- Hypotension/shock: SBP ≤90 mmHg or orthostatic syncope — hallmark of TSS [2]
- Rapid progression: Multiorgan failure in as little as 8–12 hours [2]
- Altered mental status: Confusion, agitation without focal neurologic signs [2]
- ARDS/respiratory distress: Pulmonary involvement from capillary leak [6]
- DIC: Coagulopathy, petechiae, bleeding [7]
- Oliguria/anuria: Renal failure (BUN/Cr >2× upper limit of normal) [2]
- Necrotizing fasciitis: Disproportionate pain, crepitus, dusky skin — more common in streptococcal TSS [4]
3. Medications
Treatments:
- Clindamycin 600–900 mg IV q8h — suppresses toxin production; superior to beta-lactams alone for toxin-mediated disease [2][8-9]
- Anti-staphylococcal beta-lactam (nafcillin/oxacillin) or cephalosporin for staphylococcal TSS [1]
- Penicillin G + clindamycin for streptococcal TSS (IDSA recommendation) [8]
- Vancomycin if MRSA suspected [1]
- Linezolid as alternative to clindamycin if resistance is present [2][10]
- IVIG (1–2 g/kg): Consider in refractory cases not improving with aggressive support and source control [2][11]
- Vasopressors for fluid-refractory shock
Medication contributors/cautions:
- NSAIDs: Associated with increased risk of streptococcal TSS, particularly in children with varicella [4]
- Avoid relying on blood cultures alone for diagnosis — positive in <5% of staphylococcal TSS [2]
4. Diet
- NPO if hemodynamically unstable or altered mental status
- Aggressive IV fluid resuscitation is the priority — massive capillary leak requires large-volume crystalloid and potentially colloid [6]
- Advance diet as clinical status improves
5. Review of Systems
- Constitutional: Fever, chills, rigors, severe malaise
- GI: Vomiting, profuse watery diarrhea (early and prominent)
- MSK: Severe diffuse myalgia
- Skin: Diffuse erythema ("sunburn rash"), later desquamation (palms/soles at 10–21 days)
- Neuro: Confusion, agitation, lethargy, syncope
- GU: Vaginal discharge, dysuria, oliguria; sterile pyuria in >50% [12]
- Mucosal: Conjunctival injection, oropharyngeal hyperemia, "strawberry tongue"
- Respiratory: Dyspnea, cough (ARDS)
6. Collateral History and Family History
- Collateral: Menstrual product use details from patient or family; recent surgery, wound care, nasal packing, burns
- Recurrence history: Menstrual TSS recurs in up to 30–40% if not treated with anti-staphylococcal antibiotics; non-menstrual recurrence is rare [2]
- Household contacts: For streptococcal TSS, close contacts may need prophylaxis [11]
- Family history is generally not contributory, though absence of protective anti-TSST-1 antibodies (more common in young adults) is a host susceptibility factor [13]
7. Risk Factors
- Menstrual TSS: Tampon use (especially high-absorbency), menstrual cup use, prolonged wear >8 hours [5]
- Non-menstrual TSS: Postsurgical wounds (within 48 hours), postpartum/postabortion, burns, soft tissue infections, nasal packing, foreign bodies [1-2]
- Age: Young adults and children — lower prevalence of protective anti-TSST-1 antibodies [13]
- Immunocompromised: Absence of neutralizing antibodies [13]
- Varicella: Risk factor for streptococcal TSS in children [4]
- NSAID use: May mask symptoms and increase risk of invasive streptococcal disease [4]
- Vaginal microbiome: Dysbiotic vaginal flora and Candida co-colonization may promote TSST-1 production [14-15]
- IUD use: Associated with higher vaginal S. aureus colonization [16]
8. Differential Diagnosis
- Septic shock (other etiologies): Positive blood cultures, identifiable source
- Meningococcemia: Petechial/purpuric rash (not diffuse erythroderma), positive blood/CSF cultures
- Rocky Mountain spotted fever: Petechial rash starting at wrists/ankles, tick exposure history [17]
- Scarlet fever: Sandpaper rash, pharyngitis, less hemodynamic compromise
- Kawasaki disease (pediatrics): Younger age, coronary artery involvement, thrombocytosis (vs. thrombocytopenia in TSS) [18]
- MIS-C: COVID-19 association, cardiac dysfunction, lymphopenia [19]
- Necrotizing fasciitis without TSS: Disproportionate pain, may lack diffuse rash
- Stevens-Johnson syndrome/TEN: Mucosal involvement, drug exposure, target lesions
- AGEP: Drug-induced, delayed pustule formation, recent beta-lactam exposure [20]
- Staphylococcal scalded skin syndrome: Nikolsky sign positive, more common in neonates/young children
- Leptospirosis: Travel/exposure history, conjunctival suffusion [17]
- Drug reaction (DRESS): Eosinophilia, drug exposure, slower onset
9. Past Medical History
- Prior TSS episodes: Recurrence risk is significant for menstrual TSS [2]
- Recent surgery or procedures (within 48 hours)
- Recent childbirth or abortion
- Chronic skin conditions or wounds
- Immunosuppression: HIV, chemotherapy, transplant
- Varicella or recent viral illness (children)
10. Physical Exam
Vital signs:
- Fever ≥38.9°C (102°F) — universal [2]
- Hypotension: SBP ≤90 mmHg or orthostatic changes [2]
- Tachycardia: Often marked
Skin:
- Diffuse macular erythroderma ("sunburn-like" rash) — early finding [2]
- Desquamation of palms and soles — late finding at 10–21 days [2]
- Inspect for wound infections, cellulitis, necrotizing fasciitis
Mucosal:
- Conjunctival hyperemia
- Oropharyngeal hyperemia, "strawberry tongue"
- Vaginal hyperemia — perform pelvic exam; remove any retained tampon or foreign body [2]
Focused exam:
- Surgical wounds — may appear benign despite TSS [2]
- Assess for soft tissue crepitus, disproportionate pain (necrotizing fasciitis)
- Neurologic: Altered sensorium without focal deficits [2]
11. Lab Studies
Recommended initial labs:
- CBC: Thrombocytopenia (platelets ≤100 × 10⁹/L), anemia, leukocytosis with left shift [1][12]
- BMP: Elevated BUN/creatinine (≥2× ULN), hypocalcemia [12]
- LFTs: Elevated AST/ALT, bilirubin (≥2× ULN) [2]
- CK: Elevated (myositis marker) [2]
- Coagulation studies: PT/INR, PTT, fibrinogen, D-dimer — assess for DIC [1]
- Lactate: Marker of tissue hypoperfusion
- Blood cultures: Obtain but often negative in staphylococcal TSS (<5% positive); more commonly positive in streptococcal TSS [2]
- Wound/vaginal cultures: Higher yield for organism identification [12]
- Urinalysis: Sterile pyuria in >50% [12]
- Albumin: Low (capillary leak) [12]
Rule-out labs:
- Blood/CSF cultures to exclude meningococcemia, other bacteremia
- Serologies for RMSF, leptospirosis, measles (per CDC criteria) [2]
12. Imaging
- Chest X-ray: Evaluate for ARDS, pulmonary edema (capillary leak)
- CT with contrast: If necrotizing fasciitis suspected (streptococcal TSS) — look for fascial thickening, gas in soft tissues, fluid tracking
- Echocardiography: If myocardial dysfunction suspected (myocardial failure is a recognized complication) [6]
- Imaging is not required for diagnosis — TSS is a clinical diagnosis [1]
13. Special Tests
Diagnostic criteria (CDC — Staphylococcal TSS): [2]
- Fever ≥38.9°C
- Diffuse macular erythroderma
- Desquamation (1–2 weeks after onset)
- Hypotension (SBP ≤90 mmHg)
- ≥3 organ systems involved (GI, muscular, mucosal, renal, hepatic, hematologic, CNS)
- Negative alternative diagnoses (RMSF, leptospirosis, measles)
- Confirmed: All 6 criteria met
- Probable: 5 of 6 criteria met [2]
Streptococcal TSS criteria: Isolation of GAS + hypotension + ≥2 signs of severity (renal impairment, coagulopathy, hepatic involvement, ARDS, rash, soft tissue necrosis) [2]
Point-of-care:
- Bedside ultrasound for cardiac function, IVC assessment for volume status
- POCUS for soft tissue assessment if necrotizing fasciitis suspected
14. ECG
- Indications: All patients — assess for myocardial involvement
- Findings: Sinus tachycardia (most common), ST-segment changes, low voltage (myocarditis/pericarditis), arrhythmias
- Myocardial failure is a recognized complication of TSS [6]
- Obtain troponin and BNP if cardiac involvement suspected
15. Assessment
TSS is a clinical diagnosis based on CDC criteria; do not delay treatment waiting for confirmatory testing. [1] Key clinical pearls:
- The classic triad is fever + diffuse erythroderma + hypotension with multiorgan involvement [2]
- TSS can present without rash — maintain high suspicion in any febrile patient with unexplained shock, especially postoperative or menstruating [21]
- Staphylococcal TSS: Blood cultures positive in <5%; infection focus often superficial or occult [2]
- Streptococcal TSS: Deeper infection foci (necrotizing fasciitis, myositis); bacteremia more common; higher mortality (30–80% in adults) [4]
- Progression from onset to multiorgan failure can occur in 8–12 hours [2]
16. Treatment Plan
Initial stabilization (ED):
- Aggressive IV fluid resuscitation: Large-volume crystalloid (often 4–10 L in first 24 hours due to massive capillary leak); consider albumin [6]
- Vasopressors (norepinephrine) for fluid-refractory hypotension
- Source control: Immediately remove any foreign body (tampon, nasal packing); drain abscesses; surgical debridement for necrotizing fasciitis [1][11]
Antibiotics — start empirically and immediately: [1-2][8]
Adjunctive therapy:
- IVIG (1–2 g/kg): Consider in cases failing to improve with aggressive support and source control; neutralizes circulating superantigens [2][11]
- Linezolid: Alternative to clindamycin if resistance is present [2][10]
17. Disposition
- All confirmed or suspected TSS requires ICU admission [5][7]
- Early surgical consultation if necrotizing fasciitis, deep soft tissue infection, or abscess requiring debridement [21]
- Infectious disease consultation recommended
- No outpatient management is appropriate for TSS — >95% survival with early appropriate therapy [6]
18. Follow Up / Return Precautions
Inpatient:
- Monitor for ARDS, myocardial failure, DIC, renal failure — common subacute complications [6]
- Expect desquamation of palms/soles at 10–21 days (confirms diagnosis retrospectively) [2]
- Repeat labs (CBC, BMP, LFTs, coags) serially to track organ recovery
Post-discharge:
- Menstrual TSS: Counsel to avoid tampon use — recurrence rate is significant without behavioral modification and adequate antibiotic treatment [2][6]
- Complete anti-staphylococcal antibiotic course to eradicate colonization and reduce recurrence [6]
- Follow-up with infectious disease and primary care within 1–2 weeks
- Return immediately for: recurrent fever, rash, hypotension, vomiting/diarrhea, confusion, or any signs of relapse
- Expected recovery: Most patients recover fully if treated early; prolonged fatigue, hair/nail loss, and memory difficulties may persist for weeks to months
References
1. The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature. — Gottlieb M, Long B, Koyfman A. The Journal of Emergency Medicine. 2018.
2. The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature. — Gottlieb M, Long B, Koyfman A. The Journal of Emergency Medicine. 2018.
3. The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature. — Gottlieb M, Long B, Koyfman A. The Journal of Emergency Medicine. 2018.
4. Gram-Positive Toxic Shock Syndromes. — Lappin E, Ferguson AJ. The Lancet. Infectious Diseases. 2009.
5. Gram-Positive Toxic Shock Syndromes. — Lappin E, Ferguson AJ. The Lancet. Infectious Diseases. 2009.
6. Menstrual Toxic Shock Syndrome: Case Report and Systematic Review of the Literature. — Berger S, Kunerl A, Wasmuth S, et al. The Lancet. Infectious Diseases. 2019.
7. Menstrual Toxic Shock Syndrome: Case Report and Systematic Review of the Literature. — Berger S, Kunerl A, Wasmuth S, et al. The Lancet. Infectious Diseases. 2019.
8. Toxic Shock Syndrome in Children: Epidemiology, Pathogenesis, and Management. — Chuang YY, Huang YC, Lin TY. Paediatric Drugs. 2005.
9. Toxic Shock Syndrome in Children: Epidemiology, Pathogenesis, and Management. — Chuang YY, Huang YC, Lin TY. Paediatric Drugs. 2005.
10. Association of Characteristics of Tampon Use With Menstrual Toxic Shock Syndrome in France. — Billon A, Gustin MP, Tristan A, et al. EClinicalMedicine. 2020.
11. Association of Characteristics of Tampon Use With Menstrual Toxic Shock Syndrome in France. — Billon A, Gustin MP, Tristan A, et al. EClinicalMedicine. 2020.
12. Therapy of Toxic Shock Syndrome. — Todd JK. Drugs. 1990.
13. Therapy of Toxic Shock Syndrome. — Todd JK. Drugs. 1990.
14. Toxic Shock Syndrome Due to Streptococcus Pyogenes: Case Report. — Ganss A, Venturini S, Reffo I, et al. The Journal of Emergency Medicine. 2025.
15. Toxic Shock Syndrome Due to Streptococcus Pyogenes: Case Report. — Ganss A, Venturini S, Reffo I, et al. The Journal of Emergency Medicine. 2025.
16. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
17. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
18. Necrotising Soft-Tissue Infections. — Hua C, Urbina T, Bosc R, et al. The Lancet. Infectious Diseases. 2023.
19. Necrotising Soft-Tissue Infections. — Hua C, Urbina T, Bosc R, et al. The Lancet. Infectious Diseases. 2023.
20. Efficacy and Side-Effect Profile of Tedizolid in the Treatment of Streptococcal Toxic Shock Syndrome Due to Clindamycin-Resistant Streptococcus Pyogenes: A Case Report. — Yokota K, Kawakami K. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2024.
21. Efficacy and Side-Effect Profile of Tedizolid in the Treatment of Streptococcal Toxic Shock Syndrome Due to Clindamycin-Resistant Streptococcus Pyogenes: A Case Report. — Yokota K, Kawakami K. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2024.
22. Toxic Shock Syndrome - The Seven Rs of Management and Treatment. — Wilkins AL, Steer AC, Smeesters PR, Curtis N. The Journal of Infection. 2017.
23. Toxic Shock Syndrome - The Seven Rs of Management and Treatment. — Wilkins AL, Steer AC, Smeesters PR, Curtis N. The Journal of Infection. 2017.
24. Clinical and Laboratory Manifestations of Toxic Shock Syndrome. — Tofte RW, Williams DN. Annals of Internal Medicine. 1982.
25. Clinical and Laboratory Manifestations of Toxic Shock Syndrome. — Tofte RW, Williams DN. Annals of Internal Medicine. 1982.
26. A Randomized, Double-Blind Study on the Safety and Immunogenicity of rTSST-1 Variant Vaccine: Phase 2 Results. — Schoergenhofer C, Gelbenegger G, Hasanacevic D, et al. EClinicalMedicine. 2024.
27. A Randomized, Double-Blind Study on the Safety and Immunogenicity of rTSST-1 Variant Vaccine: Phase 2 Results. — Schoergenhofer C, Gelbenegger G, Hasanacevic D, et al. EClinicalMedicine. 2024.
28. Candida Albicans Promotes TSST-1 Production by Staphylococcus Aureus Through Glucose Depletion and Relief of CcpA-mediated Repression. — Carriou M, Badiou C, Soulard A, et al. Journal of Bacteriology. 2026.
29. Candida Albicans Promotes TSST-1 Production by Staphylococcus Aureus Through Glucose Depletion and Relief of CcpA-mediated Repression. — Carriou M, Badiou C, Soulard A, et al. Journal of Bacteriology. 2026.
30. Vaginal Community State Types (CSTs) Alter Environmental Cues and Production of the Staphylococcus Aureus Toxic Shock Syndrome Toxin-1 (TSST-1). — Maduta CS, McCormick JK, Dufresne K. Journal of Bacteriology. 2024.
31. Vaginal Community State Types (CSTs) Alter Environmental Cues and Production of the Staphylococcus Aureus Toxic Shock Syndrome Toxin-1 (TSST-1). — Maduta CS, McCormick JK, Dufresne K. Journal of Bacteriology. 2024.
32. Vaginal Tampon Colonization by Staphylococcus Aureus in Healthy Women. — Chiaruzzi M, Barbry A, Muggeo A, et al. Applied and Environmental Microbiology. 2020.
33. Vaginal Tampon Colonization by Staphylococcus Aureus in Healthy Women. — Chiaruzzi M, Barbry A, Muggeo A, et al. Applied and Environmental Microbiology. 2020.
34. Staphylococcus aureus Infections. — Lowy FD. The New England Journal of Medicine. 1998.
35. Staphylococcus aureus Infections. — Lowy FD. The New England Journal of Medicine. 1998.
36. Early Differentiation of Kawasaki Disease Shock Syndrome and Toxic Shock Syndrome in a Pediatric Intensive Care Unit. — Lin YJ, Cheng MC, Lo MH, Chien SJ. The Pediatric Infectious Disease Journal. 2015.
37. Early Differentiation of Kawasaki Disease Shock Syndrome and Toxic Shock Syndrome in a Pediatric Intensive Care Unit. — Lin YJ, Cheng MC, Lo MH, Chien SJ. The Pediatric Infectious Disease Journal. 2015.
38. Distinguishing Multisystem Inflammatory Syndrome in Children From COVID-19, Kawasaki Disease and Toxic Shock Syndrome. — Godfred-Cato S, Abrams JY, Balachandran N, et al. The Pediatric Infectious Disease Journal. 2022.
39. Distinguishing Multisystem Inflammatory Syndrome in Children From COVID-19, Kawasaki Disease and Toxic Shock Syndrome. — Godfred-Cato S, Abrams JY, Balachandran N, et al. The Pediatric Infectious Disease Journal. 2022.
40. Acute Generalized Exanthematous Pustulosis Mimicking Toxic Shock Syndrome in a Pediatric Patient. — Liao A, Shawa H, Compton L, Siegel L. Pediatric Dermatology. 2025.
41. Acute Generalized Exanthematous Pustulosis Mimicking Toxic Shock Syndrome in a Pediatric Patient. — Liao A, Shawa H, Compton L, Siegel L. Pediatric Dermatology. 2025.
42. Lesson of the Month 2: Toxic Shock Syndrome. — Shalaby T, Anandappa S, Pocock NJ, Keough A, Turner A. Clinical Medicine. 2014.
43. Lesson of the Month 2: Toxic Shock Syndrome. — Shalaby T, Anandappa S, Pocock NJ, Keough A, Turner A. Clinical Medicine. 2014.
44. Infections Caused by Clostridium Perfringens and Paeniclostridium Sordellii After Unsafe Abortion. — Aronoff DM, Marrazzo JM. The Lancet. Infectious Diseases. 2023.
45. Infections Caused by Clostridium Perfringens and Paeniclostridium Sordellii After Unsafe Abortion. — Aronoff DM, Marrazzo JM. The Lancet. Infectious Diseases. 2023.